ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 088,24
0,89%
Dow Jones
38 239,66
0,40%
DAX
18 161,01
1,32%
Brent Oil
88,165
0,00%
Bitcoin
63 441,56
0,05%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Affimed NV (AFMD)

  7. Affimed NV (AFMD) Actualités

AFMD Affimed NV

5,03
0,15 (3,07%)
27 Avr 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Affimed NV AFMD NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,15 3,07% 5,03 06:00:02
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
4,93 4,88 5,19 5,03 4,88
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
24/4/202410:05GLOBEAffimed Announces Acceptance of AFM24 Clinical Abstract at..
28/3/202411:30GLOBEAffimed Reports 2023 Financial Results and Operational..
21/3/202411:30GLOBEAffimed To Report Full Year 2023 Financial Results &..
11/3/202421:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
06/3/202412:34EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
06/3/202412:30GLOBEAffimed Announces 1-for-10 Reverse Stock Split
08/1/202422:45EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
08/1/202422:05GLOBEAffimed Provides Clinical Response Update on AFM24-102 Trial..
08/1/202414:11EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
08/1/202414:00GLOBEAffimed Announces Leadership Change and Organizational..
03/1/202412:30GLOBEAffimed Announces Sale of Wholly-Owned Subsidiary AbCheck
11/12/202312:10EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11/12/202312:02GLOBEAffimed Announces Positive Data for AFM24 in Combination..
11/12/202312:00GLOBEAffimed Announces Updated Phase 1/2 Data from Acimtamig in..
04/12/202312:30GLOBEAffimed to Host Investor Conference Call Highlighting..
30/11/202313:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
14/11/202312:30GLOBEAffimed Reports Third Quarter 2023 Financial Results and..
09/11/202312:30GLOBEAffimed Announces Acimtamig as International Nonproprietary..
07/11/202312:30GLOBEAffimed to Report Third Quarter 2023 Financial Results &..
03/11/202317:05GLOBEAffimed Presents Preclinical Data Showing that Addition of..
02/11/202314:05GLOBEAffimed Announces Oral Presentation of Phase 1/2 Data from..
01/11/202311:30GLOBEAffimed to Participate in Upcoming Investor Conferences
04/10/202312:40EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
04/10/202312:30GLOBEAffimed Announces Listing Transfer to Nasdaq Capital Markets
27/9/202315:05GLOBEAffimed Announces Acceptance of an Abstract Comparing NK..
21/9/202312:30GLOBEAffimed to Present at the Cantor Global Healthcare..
12/9/202312:30GLOBEAffimed Receives FDA Fast Track Designation for AFM13 in..
07/9/202312:30GLOBEAffimed to Present at the H.C. Wainwright Annual Global..
22/8/202311:00GLOBEAffimed Announces Publication in the Journal mAbs on..
10/8/202312:45EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
10/8/202312:30GLOBEAffimed Reports Second Quarter 2023 Financial Results and..
03/8/202312:30GLOBEAffimed to Report Second Quarter 2023 Financial Results..
31/7/202323:05GLOBEAffimed Announces an ASCO Breakthrough Poster Presentation..
22/6/202312:30GLOBEAffimed Announces Addition of Dr. Constanze Ulmer-Eilfort to..
09/6/202323:59GLOBEAffimed Announces Acceptance of Abstracts at the 17th..
03/6/202315:00GLOBEAffimed Presents AFM24 Monotherapy Data in Non-Small Cell..
30/5/202312:30GLOBEAffimed to Present at the 2023 Jefferies Healthcare..
25/5/202323:00GLOBEAffimed Announces Publication of AFM24 Clinical Abstracts..
23/5/202312:30GLOBEAffimed Reports First Quarter 2023 Financial Results and..
23/5/202312:15GLOBEAffimed Announces IND Clearance for a Phase 2 Clinical Trial..
22/5/202312:30GLOBEAffimed Announces Annual General Meeting of Shareholders
16/5/202312:30GLOBEAffimed to Report First Quarter 2023 Financial Results &..
11/5/202316:05GLOBEAffimed Announces Abstracts at the Annual Meeting of the..

Dernières Valeurs Consultées

NASDAQ
AFMD
Affimed NV
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés